基因工程干扰素与中药制剂并用抗乙型肝炎肝纤维化的临床研究

为寻找治疗乙型肝炎肝纤维化的有效措施。方法；应用ａ１型基因工程干扰素（ＩＦＮ－ａ１）和中药制剂治疗乙型肝炎肝纤维化患者４０例，并观察治疗前后血清层粘蛋白、Ⅲ型前胶原、透明质酸、肝活检、Ｂ超、纤维胃镜等指标变化。结果：治疗３个月后，肝纤维化血清指标获得明显下降，与治疗前比较具有显著性差异（Ｐ＜０．００１）；肝活检、Ｂ超、纤维胃镜证实肝纤维化获得改善；疗程结束６个月时，测定血清肝纤维化指标及白蛋白、球蛋白，ＩＦＮ－ａ１效应型与无效应型比较也具有显著性差异（Ｐ＜０．００１）。结论：应用ＩＦＮ－ａ１抑制乙型肝炎病毒复制、中药制剂抗肝纤维化具有较好疗效。

英文摘要:

To find the effective method of curing hepatic fibrosis of hepatitis B. Methods: Using interferon a1and Chinese medical preparation to treat patients with hepatic fibrosis of hepatitis B and the comprehensive indexes,including levels of laminin, precollagen type Ⅲ and hyaluronic acid, liver puncture, ultrasonographic and fiber-gastroscopic examination were observed before and after treatment. Results:After 3 months of treatment, the fibroticindexes lowered obviously,in comparing with those before treatment, the difference was significant (P<0. 001 ).Liver biopsy, B-type ultrasonographic and fiber-gastroscopic examination proved that the hepatofibrosis was improved. The hepato-fibrotic indexes, blood albumin and globulin level were re-examined after 6 months, resultsshowed that the difference between the IFN-effective group and the IFN-ineffective group was significant, P<0.001. Conclusions:Beneficial effect might be obtained by using IFN-a1 to suppress the replication of hepatitis Bvirus and Chinese medical preparation to treat hepatic fibrosis.

关闭